<DOC>
	<DOCNO>NCT00079716</DOCNO>
	<brief_summary>The purpose study determine safety activity SGN-40 weekly dosage schedule single agent .</brief_summary>
	<brief_title>Study SGN-40 Patients With Refractory Recurrent Multiple Myeloma</brief_title>
	<detailed_description>This open-label , multi-dose , single-arm , phase I , dose-escalation study define toxicity profile , maximum tolerate dose ( MTD ) , pharmacokinetics , antitumor activity SGN-40 patient refractory recurrent multiple myeloma . A minimum three patient enter dose-level cohort . All patient receive dose-loading schedule first two week . The maximum weekly dose 16mg/kg .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Patients must refractory recurrent secretory multiple myeloma ( MM ) . 2 . Patients must fail least two different prior systemic therapy MM . 3 . Patients may receive maximum five cytotoxic regimen . 4 . Patients receive follow must complete within specified time frame : Autologous stem cell transplant 12 week prior first dose Nitrogen Mustard agent , Melphalan , BCNU , IVIG , monoclonal antibody therapy 6 week prior first dose Chemotherapy , Radiation , therapies MM 4 week prior first dose 5 . Patients undergone autologous stem cell transplantation must either ineligible stem cell transplantation , eligible , must refuse treatment autologous stem cell transplantation . 6 . Patients must ECOG performance status ≤ 2 life expectancy &gt; three month . 7 . Patients must available periodic blood sampling , studyrelated assessment , management toxicity treat institution entire duration study . 8 . Patients must least 18 year age . 9 . Females childbearing potential must negative βHCG pregnancy test result within three day enrollment . All patient must plan use effective contraceptive method course study . 10 . Patients must meet baseline lab data requirement . 11 . Patients must give write informed consent . 1 . Patients nonsecretory MM solitary plasmacytoma plasma cell leukemia . 2 . Patients history allogeneic transplantation . 3 . Patients receive plasmapheresis within four week prior enrollment . 4 . Patients undergo major surgery within four week prior enrollment . 5 . Patients know hypersensitivity recombinant proteins excipient contain drug formulation . 6 . Patients history malignancy past five year exception adequately treat basal squamous cell skin cancer cervical carcinoma situ . 7 . Patients active viral , bacterial , systemic fungal infection within four week enrollment . 8 . Patients history significant chronic recurrent infection require treatment . 9 . Patients history active thrombosis within three month enrollment . 10 . Patients history pulmonary embolism . 11 . Patients history migraine severe headache require medical therapy within 12 month enrollment . 12 . Patients pregnant breastfeeding . 13 . Patients uncontrolled hypercalcemia . 14 . Patients serious underlying medical condition would impair ability receive tolerate plan treatment . 15 . Patients dementia alter mental status would preclude understand render informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antigens , CD40</keyword>
	<keyword>Antibody , Monoclonal</keyword>
	<keyword>Blood Coagulation Disorders</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Hemorrhagic Disorders</keyword>
	<keyword>Hemostatic Disorders</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Paraproteinemias</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Antibody-Dependent Cell Cytotoxicity</keyword>
</DOC>